Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

By J. Baselga, D. Pfister, M. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, Larry Norton, K. Gunnett and 4 more. Journal of Clinical Oncology, 2000

772 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/0e60cc96411be8b47a1914b727eb60af1854bbd0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. R. Jove
2. J. Baselga
3. Fortunato Ciardiello
4. J. Mendelsohn
5. Jacqueline F. Bromberg

In Radiology, Nuclear Medicine and Imaging

1. R. Jove
2. J. Baselga
3. J. Mendelsohn
4. J. Turkson

Citations in the corpus

• STAT proteins: novel molecular targets for cancer drug discovery (2000, background): “Use of receptor neutralizing antibody, for example, C225, anti-EGF-R antibodies, and herceptin, anti-HER2 antibodies, as therapeutic approaches is currently being exploited in clinical trials (Baselga et al., 1996, 1998, 2000).”
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001, background): “IMC-C225 has nonlinear pharmacokinetics, with antibody doses in the range of 200–400 mg/m(2) being associated with complete saturation of systemic clearance (37).”
• The EGF receptor family as targets for cancer therapy (2000, background): “Preliminary analysis of skin biopsies from patients participating in the phase I trials have shown that ZD1839 results in substantial changes in EGFr dependent molecules such as phospho-MAPK, p27KIP1, phospho-STAT3 and others (Baselga et al., 2000b).”
• ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. (2002, background): “, C225 (66)] and small molecule approaches [e.”